Feeds
Not taking your medicines as prescribed can hurt your wallet as well as your health and far outweigh any savings on your pharmacy bill.
Lipitor, the best-selling drug in the history of pharmaceuticals, is the blockbuster that almost wasn't.
Three prominent senators are demanding that drugmaker Pfizer Inc. produce documents about its deals with insurers to get them to cover its cholesterol blockbuster Lipitor, rather than two generic versions just hitting drugstores.
Two chemicals considered harmful to babies remain in Johnson & Johnson's baby shampoo sold in the U.S., even though the company already makes versions without them, according to a coalition of health and environmental groups.
When France's top drugmaker lured Christopher Viehbacher away from a British rival in late 2008, the hope was he would be a savior.
Merck & Co. Inc., which reports its third-quarter results before the stock markets open Friday, will discuss launch plans for some newly approved drugs — two of which are likely blockbusters — along with a joint venture sale and some executive changes.
Drugmaker Bristol-Myers Squibb Co., which will report third-quarter results before the stock market opens Thursday, likely will focus on early sales of three recently approved drugs, trends for top seller Plavix as generic competition looms and an update of its research.
Health care giant Johnson & Johnson likely will discuss its pipeline, recent drug approvals and several important deals when it reports its third-quarter results before the stock market opens Tuesday.
Pfizer Inc. and a pharmacy standards group are teaming to warn consumers about the risks of counterfeit prescription medicines, which endanger the public and take money from both pharmacies and legitimate drugmakers.
A drug for dangerously high blood pressure, normally priced at $25.90 per dose, offered to hospitals for $1,200. Fifteen deaths in 15 months blamed on shortages of life-saving medications.
Drugmaker AstraZeneca PLC's big gamble, an attempt to prove its top-selling drug works better than rival cholesterol blockbuster Lipitor, appears to have backfired.
The maker of the world's best-selling diabetes drug is facing hundreds of lawsuits and likely a big sales drop as suspicion grows that taking the pill for more than a year raises the risk of bladder cancer.
Pfizer Inc., which reports second-quarter results before the stock market opens Tuesday, will discuss a few recent drug approvals, new data on some experimental drugs and plans to divest some of its non-core businesses.
Drugmaker Bristol-Myers Squibb Co., which will report second-quarter results before the stock market opens Thursday, likely will focus on three recently approved drugs and their launches, plus issues with a key experimental diabetes drug.
The cost of prescription medicines used by millions of people every day is about to plummet.
Health care giant Johnson & Johnson likely will tout an impressive three recent drug approvals, and downplay still-more medicine recalls, when it reports its second-quarter results before the stock market opens Tuesday.
A three-judge federal appeals court panel on Monday rejected an attempt by drugmaker Merck & Co. to win a refund of nearly $500 million in taxes assessed two decades ago.
Looking to hold down your health care costs? Vaccines are a cost-effective way to reduce health risks, but they are often overlooked by adults.
A much-anticipated drug for advanced lung cancer from Pfizer Inc. appears to double survival over standard drugs against tumors with a certain genetic mutation, according to research presented Sunday.
UNICEF is for the first time publicizing what drugmakers charge it for vaccines, as the world's biggest buyer of lifesaving immunizations aims to spark price competition in the face of rising costs.
Bayer is looking for a speedy remedy for stagnant aspirin sales.
Pfizer Inc., which reports first-quarter results before the stock market opens Tuesday, likely will focus on a recent acquisition, promising data on some experimental drugs and efforts to improve its business portfolio under CEO Ian Read, who took over in December.
Johnson & Johnson's chief executive told shareholders at their annual meeting Thursday that the company will come back "stronger than ever" after addressing quality problems that led to an astounding string of product recalls.
Merck & Co., which reports its first-quarter results before the stock market opens Friday, likely will discuss its just-approved skin cancer drug, a big litigation settlement and how it will address another round of generic competition.
Drugmaker Bristol-Myers Squibb Co., which recently got approval of an important new skin cancer drug but is facing a sharp revenue drop next year, will report first-quarter results before the stock market opens Thursday.
Log In | Register
